All News Emyria Limited

Equities

Delayed Australian S.E. Other stock markets 22:26:58 2024-06-27 EDT			5-day change	1st Jan Change
0.042 ^AUD	+2.44%		-4.55%	-19.23%

06-20	Emyria to Facilitate PTSD Treatment Trial	MT
06-11	Emyria CFO Steps Down	MT

Emyria to Facilitate PTSD Treatment Trial	06-19	MT
Emyria CFO Steps Down	06-10	MT
Emyria to Raise AU$2.3 Million via Placement	04-22	MT
Emyria opens Empax Centre to target care gaps in resistant PTSD	04-10	AQ
Emyria Launches Empax Center	04-09	MT
Emyria's Second Psychiatrist Receives Authorized Prescriber Status from TGA	04-04	MT
Emyria Signs Study Agreement for MDMA-Assisted Therapy; Shares Up 7%	04-02	MT
Emyria Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Emyria Secures AU$2.5 Million R&D Tax Rebate for Fiscal Year 2023	01-14	MT
Australian Medical Regulator Grants ‘Authorized Prescriber’ Status to Emyria’s Specialist Psychiatrist; Shares Soar 19%	01-09	MT
Emyria welcomes top healthcare leader as chairman	11-22	AQ
Emyria Limited Appoints Greg Hutchinson as Director	11-21	CI
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules	11-15	MT
Emyria Limited Announces Board Changes	11-12	CI
Emyria hails strong growth in clinical billings	23-10-26	AQ
Emyria Secures Canadian Regulatory Clearance to Import MDMA to Australia; Shares Fall 3%	23-10-18	MT
Emyria Begins MDMA Therapy Trials on PTSD Patients	23-10-10	MT
Emyria set to begin MDMA study after securing local supply	23-09-26	AQ
Emyria Secures Local Supply of Psychedelic Drug for Upcoming Trial; Shares Rise 3%	23-09-20	MT
Emyria Completes Pax Center Acquisition	23-09-13	MT

No results for this search